Fig. 4

Circulating EVs affect the response to Pembrolizumab in BRAF wt MM cells and responder PDOs A Bar plots showing the % of LND-1 cell viability, reported as mean ± SD, treated with 20 µg/mL Pembrolizumab (Pem) for 72 h, with the addition or not of activated PBMCs from a MM responder patient (*p < 0.05, **p < 0.01), B in presence of circulating EVs from NRES, long RES and RES > PRO (*p < 0.05). C Bar plots showing the viability (%) of MM responder patient PDOs, reported as mean ± SD, treated with 20 µg/mL Pembrolizumab for 72 h, with the addition or not of activated autologous PBMCs, in presence or absence of circulating EVs from NRES, long RES and RES > PRO (before and after ICI)